A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Sponsor

Alcon Research (Industry)

Overall Status

Completed

CT.gov ID

NCT00293761

Collaborator

(none)

109

Enrollment

Arms

3.9

Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension

Condition or Disease	Intervention/Treatment	Phase
Open-angle Glaucoma Ocular Hypertension	Drug: Travoprost, Investigational Drug: Travoprost (TRAVATAN)	Phase 3

Study Design

Study Type:

Interventional

Actual Enrollment :

109 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Treatment

Study Start Date :

Jan 1, 2006

Actual Primary Completion Date :

May 1, 2006

Actual Study Completion Date :

May 1, 2006

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Travatan, Investigational	Drug: Travoprost, Investigational One drop in study eye once daily for 13 days
Active Comparator: Travatan	Drug: Travoprost (TRAVATAN) One drop in study eye once daily for 13 days Other Names: TRAVATAN

Arm

Intervention/Treatment

Experimental: Travatan, Investigational

Drug: Travoprost, Investigational

One drop in study eye once daily for 13 days

Active Comparator: Travatan

Drug: Travoprost (TRAVATAN)

One drop in study eye once daily for 13 days

Other Names:

TRAVATAN

Outcome Measures

Primary Outcome Measures

Mean IOP []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adult patients of either sex of any race diagnosed with open-angle glaucoma (with or without pseudoexfoliation or pigment dispersion component) or ocular hypertension.
Other protocol-defined inclusion criteria may apply.